NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Unconfirmed

**Date:** Wednesday 6 September 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Andrew Makin Present for all items
4. Mariana Bacelar Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Bushra Hasnie Present for all items
7. Dr Warren Linley Present for all items
8. Dr Hatim Abdulhussien Present for all items
9. Professor David McAllister Present for all items
10. Dr Rhiannon Owen Present for all items
11. Anna Pracz Present for all items
12. Gabriel Rogers  Present for all items
13. Dr Toby Smith Present for all items
14. Mary Weatherstone Present for all items
15. Nigel Westwood Present for all items
16. Peter Wheatley-Price Present for all items
17. Tony Wootton Present for all items

NICE staff (key players) present

Richard Diaz, Associate Director Items 1.1 to 4.3.2

Jeremy Powell, Project Manager Items 1.1 to 4.3.2

Janet Robertson, Associate Director Items 5.1 to 5.3.2

Thomas Feist, Project Manager Items 5.1 to 5.3.2

Adam Brooke, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Summaya Mohammad, Heath Technology Assessment Analyst

 Items 1.1 to 4.3.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Emilene Coventry, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Marcia Miller, Administrator, Technology Appraisals Items 1.1 to 4.3.2

Rumana Zaman, Administrator, Technology Appraisals Items 5.1 to 5.3.2

**External assessment group representatives present**

Caroline Farmer, Peninsula Technology Assessment Group (PenTag)

 Items 1.1 to 4.2.1

Darren Barns, Peninsula Technology Assessment Group (PenTag)

 Items 1.1 to 4.2.1

Kate Ren, School of Health and Related Research (ScHARR) Items 5.1 to xx

Aline Navega-Biz, School of Health and Related Research (ScHARR) Items 5.1 to xx

Clinical, Patient & NHS England experts present

Carol-Anne Partridge, Patient expert nominated by CDKL5 Items 1.1 to 4.1.3

Dr Sam Amin, Clinical Expert, nominated by BPNA Items 1.1 to 4.2.1

Fiona Marley, Head of Highly Specialised Commissioning- NHS Commissioning expert Items 1.1 to xx

Peter Clark, NHS England Cancer Lead Items 5.1 to 5.3.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The vice chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Alistair Patton, Dr Andrew Makin, Dr Francis Drobniewski, Gabriel Rogers, Dr Hatim Abdulhussien, Professor Iolo Doull, Peter Wheatley Price, Dr Rhiannon Owen, Dr Stuart Williams and Dr Veline L’Esperance.

### News and announcements

### Vanessa Danielson – new committee member

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 2 August 2023
1. **Appraisal** [**of ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948)
	1. Part 1 – Open session
		1. The Vice Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Orion Pharma.
		2. The vice chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948).
		3. The Vice Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh and Adam Brooke.
	2. Part 2a – Closed session (members of the public, patient expert and company were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (clinical expert, and external assessment group were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10948>.
1. **Appraisal of** [**Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta10730)
	1. Part 1 – Open session
		1. The vice chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis Pharmaceuticals.
		2. The vice chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10730).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh.
	2. Part 2 Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10730>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 4 October and will start promptly at 9:30.